Ginkgo Bioworks Holdings, Inc. (DNA)Healthcare | Biotechnology | Boston, United States | NYSE
6.96 USD
-0.30
(-4.132%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.03 +0.07 (1.006%) ⇧ (Aug. 28, 2026, 7:50 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:58 a.m. EDT
The investment case here is fundamentally broken. Despite a recent price rebound, the company is hemorrhaging cash with negative free cash flow and operating cash flow, while revenue has contracted sharply. The balance sheet is precarious, carrying debt that exceeds its cash reserves, forcing it to rely on capital markets for survival. The market has correctly priced this as a distressed asset; the stock trades at a premium to book value despite generating no earnings and burning through resources. There is no sustainable path to profitability visible in the current trajectory, making this a dangerous hold for any investor seeking capital preservation or growth. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.135566 |
| AutoETS | 0.175196 |
| AutoTheta | 0.185383 |
| MSTL | 0.185611 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.179 |
| Excess Kurtosis | -1.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 96.152 |
| Revenue per Share | 2.26 |
| Market Cap | 468,688,352 |
| Forward P/E | -2.40 |
| Beta | 1.79 |
| Profit Margins | -219.61% |
| Website | https://www.ginkgo.bio |
As of Aug. 22, 2026, 3:58 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume relative to calls, creating a 'bear put' skew where downside protection is significantly cheaper than upside leverage. Open interest is concentrated at strikes well below the current price, suggesting a floor expectation rather than a rally thesis. Call activity is sparse and mostly centered on near-term expirations, indicating limited speculative appetite for immediate upside.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.34119785 |
| Address1 | 27 Drydock Avenue |
| Address2 | 8th Floor |
| All Time High | 634.56 |
| All Time Low | 5.0 |
| Ask | 6.96 |
| Ask Size | 500 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,271,590 |
| Average Daily Volume3 Month | 1,187,153 |
| Average Volume | 1,187,153 |
| Average Volume10Days | 1,271,590 |
| Beta | 1.789 |
| Bid | 6.95 |
| Bid Size | 1,300 |
| Board Risk | 10 |
| Book Value | 6.597 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.96 |
| Current Ratio | 4.572 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.285 |
| Day Low | 6.9199 |
| Debt To Equity | 96.152 |
| Display Name | Ginkgo Bioworks |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -261,624,992 |
| Ebitda Margins | -1.97571 |
| Enterprise To Ebitda | -2.181 |
| Enterprise To Revenue | 4.309 |
| Enterprise Value | 570,638,336 |
| Eps Current Year | -3.2 |
| Eps Forward | -2.9 |
| Eps Trailing Twelve Months | -5.11 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.3798 |
| Fifty Day Average Change | -1.4197998 |
| Fifty Day Average Change Percent | -0.16943122 |
| Fifty Two Week Change Percent | -34.119785 |
| Fifty Two Week High | 17.58 |
| Fifty Two Week High Change | -10.62 |
| Fifty Two Week High Change Percent | -0.6040956 |
| Fifty Two Week Low | 5.37 |
| Fifty Two Week Low Change | 1.5900002 |
| Fifty Two Week Low Change Percent | 0.2960894 |
| Fifty Two Week Range | 5.37 - 17.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,839,000,000 |
| Float Shares | 49,872,883 |
| Forward Eps | -2.9 |
| Forward P E | -2.3999999 |
| Free Cashflow | -72,398,248 |
| Full Exchange Name | NYSE |
| Full Time Employees | 485 |
| Fullday Change | -0.3 |
| Fullday Change Percent | -4.13223 |
| Fullday Price | 7.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.68042 |
| Gross Profits | 90,102,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04433 |
| Held Percent Institutions | 0.73557 |
| Implied Shares Outstanding | 67,340,277 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:40 |
| Long Business Summary | Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. |
| Long Name | Ginkgo Bioworks Holdings, Inc. |
| Market | us_market |
| Market Cap | 468,688,352 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_130407341 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -309,639,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 488,890,410 |
| Number Of Analyst Opinions | 2 |
| Open | 7.23 |
| Operating Cashflow | -170,243,008 |
| Operating Margins | -2.84987 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 877 422 5362 |
| Post Market Change | 0.07000017 |
| Post Market Change Percent | 1.0057496 |
| Post Market Price | 7.03 |
| Post Market Time | 1,787,961,006 |
| Previous Close | 7.26 |
| Price Eps Current Year | -2.175 |
| Price Hint | 2 |
| Price To Book | 1.055025 |
| Price To Sales Trailing12 Months | 3.5393808 |
| Profit Margins | -2.19605 |
| Quick Ratio | 4.333 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.3 |
| Regular Market Change Percent | -4.13223 |
| Regular Market Day High | 7.285 |
| Regular Market Day Low | 6.9199 |
| Regular Market Day Range | 6.9199 - 7.285 |
| Regular Market Open | 7.23 |
| Regular Market Previous Close | 7.26 |
| Regular Market Price | 6.96 |
| Regular Market Time | 1,787,947,202 |
| Regular Market Volume | 1,261,803 |
| Return On Assets | -0.16718 |
| Return On Equity | -0.59936 |
| Revenue Growth | -0.485 |
| Revenue Per Share | 2.26 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 55,383,808 |
| Shares Percent Shares Out | 0.083100006 |
| Shares Short | 5,596,447 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,208,417 |
| Short Name | Ginkgo Bioworks Holdings, Inc. |
| Short Percent Of Float | 0.1043 |
| Short Ratio | 5.58 |
| Source Interval | 15 |
| State | MA |
| Symbol | DNA |
| Target High Price | 9.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 302,163,008 |
| Total Cash Per Share | 4.487 |
| Total Debt | 404,112,992 |
| Total Revenue | 132,421,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.35065 |
| Two Hundred Day Average Change | -1.3906498 |
| Two Hundred Day Average Change Percent | -0.16653192 |
| Type Disp | Equity |
| Volume | 1,261,803 |
| Website | https://www.ginkgo.bio |
| Zip | 2,210 |